While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

Body Mass Index (BMI) is an imperfect tool for risk assessment. A patient can have a normal BMI but a high percentage of body fat—a condition called "normal weight obesity." This is a significant, yet often overlooked, risk factor for both breast cancer development and recurrence.

While beneficial for patients with prior weight loss, ruxolitinib can cause significant weight gain (20-30 pounds) in other myelofibrosis patients. This quality-of-life issue should be discussed proactively, as it can become a major concern, effectively trading one disease state for another.

The body has different estrogens: E1 (pro-inflammatory) and E2 (protective). Current breast cancer therapies are blunt instruments, blocking both types. This indiscriminate blocking contributes to negative side effects like cardiometabolic dysfunction, highlighting a need for more targeted future treatments.

When stopping GLP-1 drugs like Ozempic, hunger doesn't just return to normal; it comes back with a "ferocious, animalistic" vengeance that is far more intense than before starting the medication. This powerful rebound effect is a primary driver of rapid weight regain.

Instead of chasing weight loss, focus on foundational health markers like inflammation, blood sugar balance, stress levels, and nutrient deficiencies. When these systems are optimized, sustainable weight loss and body recomposition often occur as a natural side effect.

Chemotherapy is known to worsen metabolic parameters, but this should be viewed as an opportunity, not just a side effect. By actively correcting this metabolic dysfunction with adjunctive therapies, clinicians may be able to enhance the overall life-saving benefit of the chemotherapy itself.

Research on "The Biggest Loser" contestants revealed that metabolic slowdown is a response to significant calorie restriction and exercise. Counterintuitively, those with the largest metabolic slowdown were the most successful at losing weight and keeping it off.

GLP-1 drugs cause a precipitous drop in inflammation markers within weeks, much faster than the timeline for weight loss. This independent anti-inflammatory mechanism may explain their efficacy in conditions like knee pain and psoriasis.